HCV Patients SVR with Mavyret After Previous DAA Failure

HCV Patients SVR with Mavyret After Previous DAA Failure

DECEMBER 05, 2017
Gail Connor Roche

“The few patients who fail a primary treatment attempt with direct acting antivirals have over a 90% chance of cure using a 16-week regimen of the newly approved glecaprevir and pibrentasvir,’’ author Fred Poordad, MD, Professor of Medicine at University of Texas Health, San Antonio, told MD Magazine. “This means we should be able to cure over 99% of all hepatitis C patients.’’

Continue reading......